{"id":"dwp16001","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DWP16001 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. It also suppresses glucagon secretion and slows gastric emptying, collectively reducing postprandial and fasting blood glucose levels. The long-acting formulation allows for less frequent dosing compared to short-acting GLP-1 agonists.","oneSentence":"DWP16001 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:27.092Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07213310","phase":"PHASE1","title":"Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2025-11-09","conditions":"Healthy","enrollment":18},{"nctId":"NCT06644404","phase":"PHASE1","title":"Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2024-10-26","conditions":"Healthy","enrollment":34},{"nctId":"NCT06606093","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients","status":"NOT_YET_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2024-09-23","conditions":"Type 2 Diabetic Nephropathy","enrollment":348},{"nctId":"NCT05747664","phase":"PHASE1","title":"To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function","status":"RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2023-04-13","conditions":"Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT05466643","phase":"PHASE3","title":"A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2023-03-17","conditions":"Type 2 Diabetes Mellitus","enrollment":240},{"nctId":"NCT05505994","phase":"PHASE3","title":"The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-09-28","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders","enrollment":340},{"nctId":"NCT06141980","phase":"PHASE3","title":"Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2023-12","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":134},{"nctId":"NCT05797922","phase":"PHASE1","title":"To Evaluate the Effect of Food on the Safety and PK Characteristics of DWP16001 in Healthy Adult Volunteers","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2023-03-09","conditions":"Healthy","enrollment":32},{"nctId":"NCT05737771","phase":"PHASE1","title":"To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2023-01-25","conditions":"FDC, Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT05465668","phase":"PHASE1","title":"Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics of DWP16001 Drug A and C","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-07-22","conditions":"Healthy Volunteers","enrollment":43},{"nctId":"NCT05376969","phase":"PHASE3","title":"Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-05-25","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":159},{"nctId":"NCT04632862","phase":"PHASE3","title":"The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-11-11","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":140},{"nctId":"NCT05376930","phase":"PHASE3","title":"Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM.","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-09-16","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":63},{"nctId":"NCT04634500","phase":"PHASE3","title":"The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-11-18","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":200},{"nctId":"NCT05500898","phase":"PHASE1","title":"Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-08-26","conditions":"Healthy","enrollment":53},{"nctId":"NCT05414591","phase":"PHASE1","title":"Pharmacokinetics and Safety Following Administration of DWP16001","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-05-01","conditions":"Healthy","enrollment":38},{"nctId":"NCT05192395","phase":"PHASE1","title":"A Crossover Study of DWJ1525 to Evaluate the Safety and Pharmacokinetic Properties in Healthy Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-04-15","conditions":"Healthy","enrollment":37},{"nctId":"NCT05321732","phase":"PHASE1","title":"The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-12-10","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT04654390","phase":"PHASE3","title":"The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-12-30","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":270},{"nctId":"NCT05207176","phase":"PHASE1","title":"Study to Evaluate the Safety and PK Properties of DWP16001 in Healthy Subjects With Various Ethnicities","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-02-14","conditions":"Healthy","enrollment":24},{"nctId":"NCT04343547","phase":"PHASE1","title":"Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With DWC202001 and DWC202002 in Healthy Male Adults","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-04","conditions":"Healthy","enrollment":34},{"nctId":"NCT04064073","phase":"PHASE1","title":"Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With Metformin in Healthy Male Adults (Phase 1 Study)","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-08-14","conditions":"Healthy","enrollment":34},{"nctId":"NCT04221399","phase":"PHASE1","title":"Type 2 Diabetes Patients With Renal Impairment","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-01","conditions":"Type2 Diabetes","enrollment":35},{"nctId":"NCT03364985","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2017-12-03","conditions":"Healthy","enrollment":123},{"nctId":"NCT04014023","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-07-10","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":196}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DWP16001 tablet","DWP16001 Placebo tablet","DWP16001 0.3mg"],"phase":"phase_3","status":"active","brandName":"DWP16001","genericName":"DWP16001","companyName":"Daewoong Pharmaceutical Co. LTD.","companyId":"daewoong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DWP16001 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}